Profile
| Metric | Value |
|---|---|
| Full Name | Merck & Co., Inc. |
| Ticker | NYSE: MRK |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | General Drug Manufacturers |
| Country | United States |
| IPO | |
| Indexes | |
| Website | merck.com |
| Employees | 73,000 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $109.19 | |
| Price, 1D Change | -1.21% | |
| Market Cap | $271B | |
| TTM Dividend Yield | 3.00% | |
| PE Ratio | 14.44 | |
| Beta | 0.39 | |
| Revenue | $64B | |
| Revenue, 1Y Change | +6.85% | |
| EPS | $6.74 | |
| EPS, 1Y Change | +4,600.84% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | $0.85 | |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 131:125 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $6.74 | |
| EPS Estimate | $8.96 | |
| EPS Est. Change | +33.02% | |
| Revenue | $63.97B | |
| Revenue Estimate | $64.79B | |
| Revenue Est. Change | +1.27% | |
| Current Price | $109.19 | |
| Price Target | - | $115.00 |
| Price Tgt. Change | - | +5.32% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $1.37 | $0.14 | -89.54% | |
| $7.62 | $6.74 | -11.61% | |
| $8.96 | N/A | +33.02% | |
| $7.46 | N/A | +10.68% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $59.98B | $59.87B | -0.19% | |
| $64.00B | $63.97B | -0.04% | |
| $64.79B | N/A | +1.27% | |
| $67.99B | N/A | +6.28% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +8.13% | |
| Price, 3Y | -2.73% | |
| Market Cap, 1Y | +6.18% | |
| Market Cap, 3Y | -4.87% | |
| Revenue, 1Y | +6.85% | |
| Revenue, 3Y | +30.81% | |
| EPS, 1Y | +4,600.84% | |
| EPS, 3Y | +31.02% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $109.19 | |
| SMA 200 | $86.18 | |
| SMA 200 vs Price | -21.07% | |
| SMA 50 | $98.87 | |
| SMA 50 vs Price | -9.45% | |
| Beta | 0.39 | |
| ATR | $2.49 | |
| 14-Day RSI | 66.58 | |
| 10-Day Volatility | 17.38% | |
| 1-Year Volatility | 30.44% |
Dividends
| Metric | Date | Value |
|---|---|---|
| Last Paid | $0.85 | |
| Upcoming | N/A | N/A |
| Dividend Yield | 2.86% | |
| Total Dividend | $3.12 | |
| Dividends Paid | $7.84B | |
| Payout Ratio | 45.76% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $63.97B | |
| EPS | $6.74 | |
| Gross Profit | $47.17B | |
| Gross Margin | 73.74% | |
| Operating Profit | $20.64B | |
| Operating Margin | 6.01% | |
| Net Income | $17.13B | |
| Net Margin | 26.78% | |
| EBITDA | $25.14B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.83 | |
| Current Ratio | 1.36 | |
| Quick Ratio | 1.15 | |
| - | ||
| F-Score | 6 | |
| Altman Z-Score | 4.29 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 14.44 | |
| PS Ratio | 4.24 | |
| PB Ratio | 5.23 | |
| EV/EBITDA | 9.85 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $46.31B | |
| Cash & Equivalents | $13.77B | |
| Total Assets | $117.11B | |
| Current Assets | $38.78B | |
| Total Liabilities | $70.73B | |
| Current Liabilities | $28.42B | |
| Total Debt | $38.27B | |
| Short Term Debt | $2.93B | |
| Accounts Payable | $4.08B |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $46.86B | |
| Operating Expenses | $26.53B | |
| Cost Of Goods Sold | $16.80B | |
| SG&A | $0.00 | |
| D&A | $4.50B | |
| Interest Expense | $0.00 | |
| Income Tax | $2.80B |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $21.47B | |
| CFI | -$7.73B | |
| CFF | -$7.03B | |
| Capex | $3.37B | |
| Free Cash Flow | $18.10B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wolfe Research | → | |
| UBS | → | |
| Citigroup | → | |
| BMO Capital | → | |
| B of A Securities | → | |
| Morgan Stanley | → | |
| Scotiabank | → | |
| Goldman Sachs | → | |
| Wells Fargo | → | |
| Deutsche Bank | → |
Analyst sentiment
Institutional ownership
Screeners with MRK
Data Sources & References
- MRK Official Website www.merck.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/310158/000162828025007732/0001628280-25-007732-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- List of Dow Jones Industrial Average Companies en.wikipedia.org/wiki/Dow_Jones_Industrial_Average
- MRK Profile on Yahoo Finance finance.yahoo.com/quote/MRK
- MRK Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/mrk
FAQ
What is the ticker symbol for Merck & Co., Inc.?
The ticker symbol for Merck & Co., Inc. is NYSE:MRK
Does Merck & Co., Inc. pay dividends?
Yes, Merck & Co., Inc. pays dividends. The last payment was $0.85, with an ex-dividend date on December 15, 2025
What sector is Merck & Co., Inc. in?
Merck & Co., Inc. is in the Healthcare sector
What industry is Merck & Co., Inc. in?
Merck & Co., Inc. is in the General Drug Manufacturers industry
What country is Merck & Co., Inc. based in?
Merck & Co., Inc. is headquartered in United States
When did Merck & Co., Inc. go public?
Merck & Co., Inc. initial public offering (IPO) was on January 13, 1978
Is Merck & Co., Inc. in the S&P 500?
Yes, Merck & Co., Inc. is included in the S&P 500 index
Is Merck & Co., Inc. in the NASDAQ 100?
No, Merck & Co., Inc. is not included in the NASDAQ 100 index
Is Merck & Co., Inc. in the Dow Jones?
Yes, Merck & Co., Inc. is included in the Dow Jones index
When was Merck & Co., Inc. last earnings report?
Merck & Co., Inc.'s most recent earnings report was on October 30, 2025
When does Merck & Co., Inc. report earnings?
The next expected earnings date for Merck & Co., Inc. is February 3, 2026